Items Tagged ‘Mantle Cell Non-Hodgkin’s Lymphoma’

June 20th, 2016

CAR Therapy Effective in Advanced Lymphoma

By

According to results of several presentations at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO), chimeric antigen receptor (CAR) therapies appear to have significant anti-cancer activity among patients with different types of lymphomas. This type of treatment is continuing to produce impressive results, and is demonstrating effectiveness in several different types […]

View full entry

Tags: Advanced Stage Hodgkin's Lymphoma, Aggressive/Intermediate Grade Non-Hodgkin's Lymphoma, asco, CAR, CAR T, chimeric antigen receptor, Follicular Lymphoma, Highly Aggressive/High Grade Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Leukemia, Lymphoma, Mantle Cell Non-Hodgkin's Lymphoma


December 17th, 2014

HIV-Positive Patients with Lymphoma Should No Longer be Excluded From Receiving Blood Stem Cell Transplants as Treatment

By

HIV-positive patients with lymphoma were previously excluded from receiving autologous blood stem cell transplants as treatment, because of concern that these patients’ compromised immune systems would have a higher risk of infection and poor graft function due to their need for HIV medications. Results from the clinical trial, presented at the American Society of Hematology […]

View full entry

Tags: Aggressive/Intermediate Grade Non-Hodgkin's Lymphoma, Follicular Lymphoma, General HIV Related Cancers, Highly Aggressive/High Grade Non-Hodgkin's Lymphoma, hiv, hiv cancer, HIV Related Cancers, Indolent/Low Grade Non-Hodgkin's Lymphoma, Lymphoma, Mantle Cell Non-Hodgkin's Lymphoma, News, nhl


January 23rd, 2014

Imbruvica Approved for Mantle Cell Lymphoma

By

The U.S. Food and Drug Administration (FDA) has approved Imbruvica™ (ibrutinib) for the treatment of patients with mantle cell lymphoma, a rare and aggressive type of blood cancer. Non-Hodgkin’s lymphoma (NHL) is a form of cancer that begins in the cells of the lymph system. It is characterized by the excessive accumulation of atypical (cancerous) […]

View full entry

Tags: Mantle Cell Non-Hodgkin's Lymphoma, News, Non-Hodgkin's Lymphoma


September 4th, 2013

Celiac Disease Associated with Higher Risk of Lymphoma

By

Individuals with celiac disease have an increased risk of lymphoma, particularly if they have a condition known as persistent villous atrophy, according to the results of a large cohort study published in the Annals of Internal Medicine.[1] Celiac disease is an autoimmune disorder of the small intestine characterized by intolerance to gluten, which is a […]

View full entry

Tags: Aggressive/Intermediate Grade Non-Hodgkin's Lymphoma, Follicular Lymphoma, Health and Wellness, Highly Aggressive/High Grade Non-Hodgkin's Lymphoma, Indolent/Low Grade Non-Hodgkin's Lymphoma, Lymphoma, Mantle Cell Non-Hodgkin's Lymphoma, News, Non-Hodgkin's Lymphoma, Recurrent Non-Hodgkin's Lymphoma, Screening/Prevention Non-Hodgkin's Lymphoma, T-Cell Non-Hodgkin's Lymphoma


July 12th, 2013

Revlimid Approved for Mantle Cell Lymphoma

By

The U.S. Food and Drug Administration (FDA) has approved Revlimid® (lenalidomide) for the treatment of patients with mantle cell lymphoma whose disease has relapsed or progressed after two prior therapies, one of which included Velcade® (bortezomib). Non-Hodgkin’s lymphoma (NHL) is a form of cancer that begins in the cells of the lymph system. It is […]

View full entry

Tags: Mantle Cell Non-Hodgkin's Lymphoma, News, Non-Hodgkin's Lymphoma


July 10th, 2013

Epigenetic Therapy Promising in Mantle Cell Lymphoma

By

An epigenetic/immunotherapy regimen of cladribine, Rituxan® (rituximab), and vorinostat produced a 100 percent response rate and complete remissions in 86 percent of patients with newly diagnosed mantle cell lymphoma, according to the results of a study presented at the annual meeting of the American Association of Cancer Research in Washington D.C. Non-Hodgkin’s lymphoma (NHL) is […]

View full entry

Tags: Mantle Cell Non-Hodgkin's Lymphoma, News, Non-Hodgkin's Lymphoma


October 23rd, 2012

R-CHOP Induction Plus Rituxan Maintenance Improves Remission in Older Patients with Mantle Cell Lymphoma

By

Induction therapy with R-CHOP followed by maintenance with Rituxan® (rituximab) nearly doubled the remission duration in older patients with mantle cell lymphoma, according to the results of a study published in the New England Journal of Medicine. Non-Hodgkin’s lymphoma (NHL) is a form of cancer that begins in the cells of the lymph system. It […]

View full entry

Tags: Mantle Cell Non-Hodgkin's Lymphoma, News, Non-Hodgkin's Lymphoma


June 12th, 2012

Treanda More Effective than Standard R-CHOP for Non-Hodgkin’s Lymphoma

By

The combination of Treanda® (bendamustine) and Rituxan® (rituximab) more than doubled progression-free survival compared with standard R-CHOP therapy among patients with indolent lymphoma and mantle cell lymphoma, according to the results of a multi-center, phase III study presented at the 2012 annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois.[1] Non-Hodgkin’s […]

View full entry

Tags: Indolent/Low Grade Non-Hodgkin's Lymphoma, Mantle Cell Non-Hodgkin's Lymphoma, News, Non-Hodgkin's Lymphoma


March 14th, 2012

Lymphoma During Pregnancy Can Have Good Outcomes

By

Among women who are diagnosed with lymphoma during pregnancy, the outcomes for both mother and baby are often good. This was true for women who began lymphoma treatment during the second or third trimester of pregnancy, as well as women who deferred treatment until after delivery. These results were presented at the 2011 annual meeting […]

View full entry

Tags: Advanced Stage Hodgkin's Lymphoma, Aggressive/Intermediate Grade Non-Hodgkin's Lymphoma, Early Stage Hodgkin's Lymphoma, Follicular Lymphoma, Highly Aggressive/High Grade Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Indolent/Low Grade Non-Hodgkin's Lymphoma, Mantle Cell Non-Hodgkin's Lymphoma, News, Non-Hodgkin's Lymphoma, T-Cell Non-Hodgkin's Lymphoma


May 23rd, 2011

Many Patients with “Chemo Brain” Recover within Five Years

By

A study of “chemo brain”—the foggy thinking and forgetfulness that patients may experience after chemotherapy—suggests that the condition improves substantially over time for a majority of patients. For some patients, however, symptoms may persist for more than five years after treatment. These findings were recently reported in the Journal of Clinical Oncology. Chemo brain refers […]

View full entry

Tags: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Promyelocytic Leukemia, Adult Acute Lymphoblastic Leukemia, Advanced Stage Hodgkin's Lymphoma, Aggressive/Intermediate Grade Non-Hodgkin's Lymphoma, Allogeneic Stem Cell Transplant, Childhood Acute Lymphoblastic Leukemia, Chronic Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Early Stage Hodgkin's Lymphoma


March 15th, 2010

Children and Teens Have Better NHL Survival than Young Adults

By

Even after accounting for stage at diagnosis and subtype of non-Hodgkin’s lymphoma (NHL), children and teens with NHL have better survival than young adults with NHL. These results were published in the Archives of Pediatrics and Adolescent Medicine. Non-Hodgkin’s lymphoma (NHL) is a form of cancer that begins in the cells of the lymph system. […]

View full entry

Tags: Aggressive/Intermediate Grade Non-Hodgkin's Lymphoma, Highly Aggressive/High Grade Non-Hodgkin's Lymphoma, Indolent/Low Grade Non-Hodgkin's Lymphoma, Mantle Cell Non-Hodgkin's Lymphoma, News, Non-Hodgkin's Lymphoma, Recurrent Non-Hodgkin's Lymphoma, T-Cell Non-Hodgkin's Lymphoma